METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot for diabetes may also fight fatty liver
Disease control ENROLLING_BY_INVITATIONThis study aims to see if a combination diabetes injection (iGlarLixi) works better than a standard insulin injection (iGlar) at reducing fat in the liver. It will involve 36 adults who have both type 2 diabetes and a fatty liver condition called MASLD. Participants will receive …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Phase: PHASE4 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Apr 02, 2026 07:27 UTC
-
Phone app aims to shrink fatty liver in HIV patients
Disease control ENROLLING_BY_INVITATIONThis study is testing whether a personalized mobile phone app can help people with HIV and fatty liver disease lose weight more effectively than standard healthy lifestyle advice. About 116 participants will be randomly assigned to use the digital nutrition program or receive gen…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Phase: NA • Sponsor: Hospital Universitari de Bellvitge • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug trial aims to halt scarring in advanced fatty liver disease
Disease control OngoingThis study is testing whether an investigational drug called efinopegdutide can help treat a serious form of fatty liver disease called MASH that has progressed to cause permanent scarring (cirrhosis). About 80 adults with this condition will receive either the drug or a placebo …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC